English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Sir,We recently introduced lanthanum carbonate as an alter-native phosphate binder to sevelamer hydrochloride in pa-tients with elevated serum calcium. Lanthanum carbonatehas a higher affinity for phosphate than sevelamer HCl, sofewer lanthanum carbonate tablets are required to achievethe same phosphate control. To reduce the pill burden inpatients on high doses of sevelamer HCl, a policy of con-verting patients who were prescribed 8–12 sevelamer perday, and patients currently on 6 sevelamer per day but inneed of a dose increase, to 3 × 750 mg lanthanum car-bonate per day was established. Conversions were made atthe discretion of the doctor, so that well-controlled patientswere less likely to switch.In October 2007, 60 haemodialysis patients convertedaccording to the above criteria. Of these, 13 patients whodislikedorwereintolerantoflanthanumcarbonaterevertedto sevelamer HCl within 3 months. Forty-seven patients(68% male, median age 47 years, range 21–79) continuedto take lanthanum carbonate.Several studies have suggested that sevelamer HCl con-tributes to metabolic acidosis [1,2], while lanthanum car-bonate would be expected to have an antacid effect. Acomparison of the median of three routine (monthly) pre-dialysis serum bicarbonate and phosphate measurementsimmediately before and after conversion for each patientshowed an increase in serum bicarbonate from a meanof 20.3 ± 2.3 to 22.2 ± 2.4 mmol/l (

Correction of metabolic acidosis after conversion from sevelamer hydrochloride to lanthanum carbonate